...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in cardiovascular disease. >The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function
【24h】

The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function

机译：苯磺酸氨氯地平，氯沙坦钾，奥美沙坦美多佐美和其他降压药对中枢主动脉血压和血管功能生物标志物的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Biomarkers are being increasingly used in the study of cardiovascular disease because they provide readily quantifiable surrogate endpoints and allow accurate assessment of the effects of therapy on particular pathological processes. However, in order to be useful, biomarkers must be relevant, predictable, accurate, and reproducible. There is compelling evidence from large-scale clinical trials that inhibitors of the renin–angiotensin system [angiotensin-converting enzyme inhibitors and angiotensin type II receptor blockers (ARBs)] and calcium channel blockers (CCBs) may have beneficial effects beyond blood pressure control in the treatment of hypertension. Biomarkers are expected to provide further insight into these beneficial effects and allow for quantitative assessment. This review summarizes the published clinical evidence on the effects of various antihypertensive drugs, particularly ARBs (e.g. losartan and olmesartan medoxomil) and CCBs (e.g. amlodipine), alone and in combination with other agents (e.g. hydrochlorothiazide), on central aortic pressure and the biomarkers high-sensitivity C-reactive protein (hsCRP), adiponectin, cystatin C, homeostasis model assessment of insulin resistance (HOMA-IR), procollagen, tumor necrosis factor-α, and interleukin-6. Of these biomarkers, the benefits of antihypertensive therapy on hsCRP, adiponectin, and HOMA-IR reflect a potential for quantifiable long-term vascular benefits.
机译：由于生物标志物提供了易于量化的替代终点，并允许准确评估治疗对特定病理过程的影响，因此越来越多地用于心血管疾病的研究。然而，为了有用，生物标志物必须是相关的，可预测的，准确的和可再现的。大规模临床试验中有令人信服的证据表明，肾素-血管紧张素系统抑制剂[血管紧张素转换酶抑制剂和血管紧张素II型受体阻滞剂（ARB）]和钙通道阻滞剂（CCB）可能在控制血压方面具有有益作用。高血压的治疗。预期生物标记物将提供对这些有益作用的进一步了解，并允许进行定量评估。这篇综述总结了已发表的有关各种降压药，特别是ARB（例如氯沙坦和奥美沙坦美多美）和CCB（例如氨氯地平）单独或与其他药物（例如氢氯噻嗪）联合使用对中枢主动脉压和生物标志物的影响的临床证据。高敏C反应蛋白（hsCRP），脂联素，胱抑素C，胰岛素抵抗稳态模型评估（HOMA-IR），胶原蛋白，肿瘤坏死因子-α和白介素-6。在这些生物标志物中，抗高血压疗法对hsCRP，脂联素和HOMA-IR的益处反映了可量化的长期血管益处的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号